Compare Dyne Therapeutics Inc. Common Stock (DYN) vs VanEck Uranium & Nuclear ETF (NLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs VanEck Uranium & Nuclear ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while VanEck Uranium & Nuclear ETF trades at $94.13 (market cap $3.37B). The key difference: VanEck Uranium & Nuclear ETF is the larger of the two by market cap, and VanEck Uranium & Nuclear ETF is more actively traded (376,734 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and VanEck Uranium & Nuclear ETF for 9 Days on average.
| DYN | NLR | |
|---|---|---|
Market Cap | $2.86B | $3.37B |
Volume | 3,341,579 | 376,734 |
Sector | Health | Sector/Thematic |
52-Week High | $26.78 | $164.37 |
52-Week Low | $14.60 | $94.52 |
Typical Hold Time | 0 Days | 9 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
NLR, the VanEck Uranium and Nuclear ETF, trades at $99.38, down 0.82% on the day amid a bearish technical signal. The ETF is positioned to benefit from growing demand for nuclear power driven by AI data centers and government support, as highlighted by recent news of a major Google-Constellation deal and U.S. funding for new reactors. However, key financial ratios are unavailable, and technical indicators show selling pressure with moving averages and oscillators in bearish alignment.
The outlook for NLR is mixed, with long-term catalysts from nuclear energy adoption offset by near-term volatility and lack of transparent fundamentals. Risks include sector-specific headwinds and expense ratio comparisons, but institutional interest from firms like Bank of America suggests confidence. Investors should weigh the ETF's thematic exposure against its technical weakness and opaque financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About VanEck Uranium & Nuclear ETF
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →
